Merrill T, et al. Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE). CR 2018, abstract L14.
Vroege progressie voorspelt overleving van patiënten met sclerodermie en longfibrose
apr 2019 | ILD, Sclerodermie